NUTEX HEALTH INC (NUTX)
US67079U2078 - Common Stock
Overall NUTX gets a fundamental rating of 2 out of 10. We evaluated NUTX against 117 industry peers in the Health Care Providers & Services industry. NUTX may be in some trouble as it scores bad on both profitability and health. NUTX is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year NUTX has reported negative net income.
In the past year NUTX had a positive cash flow from operations.
NUTX had negative earnings in each of the past 5 years.
In multiple years NUTX reported negative operating cash flow during the last 5 years.
1.2 Ratios
With a Return On Assets value of -11.50%, NUTX is not doing good in the industry: 67.24% of the companies in the same industry are doing better.
With a Return On Equity value of -74.51%, NUTX is not doing good in the industry: 72.41% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -11.5% | ||
| ROE | -74.51% | ||
| ROIC | N/A |
ROA(3y)-41.95%
ROA(5y)-616.37%
ROE(3y)-178.57%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 14.05%, NUTX is doing worse than 75.00% of the companies in the same industry.
In the last couple of years the Gross Margin of NUTX has declined.
NUTX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 14.05% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-31.53%
GM growth 5YN/A
2. Health
2.1 Basic Checks
NUTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
NUTX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, NUTX has more shares outstanding
The debt/assets ratio for NUTX is higher compared to a year ago.
2.2 Solvency
NUTX has an Altman-Z score of -0.67. This is a bad value and indicates that NUTX is not financially healthy and even has some risk of bankruptcy.
NUTX has a Altman-Z score of -0.67. This is in the lower half of the industry: NUTX underperforms 69.83% of its industry peers.
NUTX has a Debt/Equity ratio of 3.96. This is a high value indicating a heavy dependency on external financing.
NUTX has a Debt to Equity ratio of 3.96. This is in the lower half of the industry: NUTX underperforms 73.28% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 3.96 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.67 |
ROIC/WACCN/A
WACC2.33%
2.3 Liquidity
NUTX has a Current Ratio of 1.56. This is a normal value and indicates that NUTX is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of NUTX (1.56) is better than 63.79% of its industry peers.
A Quick Ratio of 1.50 indicates that NUTX should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.50, NUTX is in the better half of the industry, outperforming 64.66% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.56 | ||
| Quick Ratio | 1.5 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 87.96% over the past year.
NUTX shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 12.92%.
NUTX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 377.27% yearly.
EPS 1Y (TTM)87.96%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q100%
Revenue 1Y (TTM)12.92%
Revenue growth 3Y436.91%
Revenue growth 5Y377.27%
Revenue growth Q2Q29.69%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y96.71%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year26.78%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
NUTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NUTX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of NUTX is on the same level as its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 16.31 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for NUTX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NUTEX HEALTH INC
NASDAQ:NUTX (4/26/2024, 7:07:11 PM)
0.6616
+0.01 (+1.33%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap32.88M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -11.5% | ||
| ROE | -74.51% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 14.05% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.62
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 3.96 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.56 | ||
| Quick Ratio | 1.5 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)87.96%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y96.71%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)12.92%
Revenue growth 3Y436.91%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y